A WOUND CARE COMPANY
HEALING THROUGH INNOVATION

Alerce Biologix is a premiere wound care company whose focus matches its vision in providing the latest and most effective wound care products that advance wound care efficacy and healing. We are committed to bringing to our physician partners biological products that effectively treat patients with “nonhealing wounds/ulcers” there desired result of wound closure.

 

Alerce Biologix is a premiere wound care company whose focus matches its vision in providing the latest and most effective wound care products that advance wound care efficacy and healing. We are committed to bringing to our physician partners biological products that effectively treat patients with “nonhealing wounds/ulcers” there desired result of wound closure.

 

Wound Care Program

Alerce Biologix is wholeheartedly dedicated to facilitating healthcare providers in accessing the most appropriate care modalities precisely when and where they are required.

At the core of our Healing System lies an unwavering commitment to adhering to national and international consensus Gold Standards. This unwavering dedication ensures that our esteemed clients are granted access to the most effective and rigorously evidence-based practices available.

Our Healing System embarks on its journey with an initial step of enhanced wound diagnostics. We harness cutting-edge technologies to provide an exceptionally accurate assessment of each wound’s condition. This meticulous evaluation allows us to delve into the underlying factors that may be hindering the healing process or causing other complications.

By embracing the power of advanced diagnostics, we pave the way for personalized treatments that cater precisely to the unique needs of every individual patient. This tailored approach allows us to address the distinct characteristics of each wound, ultimately resulting in significantly improved patient outcomes and an accelerated healing trajectory.

The correlation between faster healing and enhanced long-term healing rates is undeniable, and the dedicated team at Alerce Biologix is resolutely committed to empowering healthcare providers in attaining the pinnacle of patient care excellence. 

Amniotic Membrane Wound Graft

Amniotic membrane wound grafts have been effective in supporting and enhancing the body’s proper healing process. Non-healing wounds become stalled in the inflammatory phase and do not progress to the final stages of normal wound healing. Our Amniotic membrane wound grafts provide a natural scaffold structure along with numerous growth factors to jumpstart chronic wounds to a natural stage of closure.

 

  • It is a human allograft prepared from donated amniotic tissue collected using aseptic techniques during Cesarean birth. The surgical site is prepped according to AORN standards for incision disinfection. The tissue is retrieved and processed within 72 hours from time of C-section from a FDA approved tissue bank.
  • The amniotic membrane graft contains collagen, extracellular matrix, biologically active stem cells and regenerative molecules.
  • The amniotic membrane graft has been used in wound care for quite some time but new techniques to dehydrate the biological tissue has allowed for a longer shelf life.

The patients that have highest risk of chronic/nonhealing wounds that are not limited to, but include:

  • Diabetics with reduced sensation or poor circulation
  • Poor circulation in feet and legs (PAD) without diabetes
  • Patients with venous insufficiency who develop swelling in legs/feet
  • Dialysis and transplant patients
  • Patients with Raynaud’s disease with foot/toe involvement
  • Patients with rheumatoid arthritis, lupus, scleroderma
  • Patients with Neuropathy and weakened immune system
  • Lacerations/burn injuries
  • Patients that are unresponsive to other therapies for healing (periodic debridement, moist dressings, antibiotics, hyperbaric oxygen, glycemic control)
  • A thorough initial assessment of the wound is necessary, as well as medical history.
  • Gather information on history of wound, including duration and past medical treatments
  • Document wound appearance, size, and depth.
  • Assess circulatory status, nutrition, and barriers to healing.
  • After 30 days of failed conservative treatment on a wound, a patient qualifies for the Amniotic Membrane Wound Graft program.
  • Prepare the wound bed by performing any necessary debridement.
  • The wound bed should be clear of any necrotic tissue and should not have any signs of infection.
  • Wound grafts come in various sizes to fit specific dimensions of Wound site.
  • Sterile scissors may be used to cut a piece of wound membrane to fit wound more precisely.
  • Traditionally, steri-strips are used to hold graft in place. There is no need to suture the material in place.
  • The graft is replaced every 7 days because the graft dissolves.
  • After one-two weeks, the amniotic membrane wound graft should improve the wound in terms of size and depth.
  • Depending on wound site size, after a few applications, wound site closure should be achieved.
  • It is a human allograft prepared from donated amniotic tissue collected using aseptic techniques during Cesarean birth. The surgical site is prepped according to AORN standards for incision disinfection. The tissue is retrieved and processed within 72 hours from time of C-section from a FDA approved tissue bank.
  • The amniotic membrane graft contains collagen, extracellular matrix, biologically active stem cells and regenerative molecules.
  • The amniotic membrane graft has been used in wound care for quite some time but new techniques to dehydrate the biological tissue has allowed for a longer shelf life.

The patients that have highest risk of chronic/nonhealing wounds that are not limited to, but include:

  • Diabetics with reduced sensation or poor circulation
  • Poor circulation in feet and legs (PAD) without diabetes
  • Patients with venous insufficiency who develop swelling in legs/feet
  • Dialysis and transplant patients
  • Patients with Raynaud’s disease with foot/toe involvement
  • Patients with rheumatoid arthritis, lupus, scleroderma
  • Patients with Neuropathy and weakened immune system
  • Lacerations/burn injuries
  • Patients that are unresponsive to other therapies for healing (periodic debridement, moist dressings, antibiotics, hyperbaric oxygen, glycemic control)
  • A thorough initial assessment of the wound is necessary, as well as medical history.
  • Gather information on history of wound, including duration and past medical treatments
  • Document wound appearance, size, and depth.
  • Assess circulatory status, nutrition, and barriers to healing.
  • After 30 days of failed conservative treatment on a wound, a patient qualifies for the Amniotic Membrane Wound Graft program.
  • Prepare the wound bed by performing any necessary debridement.
  • The wound bed should be clear of any necrotic tissue and should not have any signs of infection.
  • Wound grafts come in various sizes to fit specific dimensions of Wound site.
  • Sterile scissors may be used to cut a piece of wound membrane to fit wound more precisely.
  • Traditionally, steri-strips are used to hold graft in place. There is no need to suture the material in place.
  • The graft is replaced every 7 days because the graft dissolves.
  • After one-two weeks, the amniotic membrane wound graft should improve the wound in terms of size and depth.
  • Depending on wound site size, after a few applications, wound site closure should be achieved.